The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events.

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya ... for Disease Control and Prevention (CDC). According to the Agencies, as ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.